KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

Abstract Background Triple-negative breast cancer (TNBC) is characterized by high rates of recurrence and poor overall survival. This is due, in part, to a deficiency of targeted therapies, making it essential to identify therapeutically targetable driver pathways of this disease. While epidermal gr...

Full description

Bibliographic Details
Main Authors: Melyssa S. Roberts, Lindsey J. Anstine, Viviane S. Finke, Benjamin L. Bryson, Bryan M. Webb, Kristen L. Weber-Bonk, Darcie D. Seachrist, Parth R. Majmudar, Ruth A. Keri
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Breast Cancer Research
Subjects:
Triple-negative breast cancer (TNBC)
Epidermal growth factor receptor (EGFR)
Krüppel-like factor 4 (KLF4)
Erlotinib
Online Access:http://link.springer.com/article/10.1186/s13058-020-01305-7

Internet

http://link.springer.com/article/10.1186/s13058-020-01305-7

Similar Items